In this educational program the effect of SGLT2 inhibitors in patients with CKD is discussed in three parts.

This course consists of the following:

• Kidney protection and SGLT2i: What do we know? - Mark Cooper, MD – Melbourne, Australia
• Targeting cardiovascular and kidney outcomes in CKD: Where do we stand today? - Maria Rosa Costanzo, MD - Naperville, IL, USA
• Targeting cardiovascular and kidney outcomes in CKD: Where do we stand today? - Prof. Christoph Wanner, MD - Würzburg, Germany

After watching these three videos, the learner should be able to:

• Reproduce epidemiology and pathophysiology of CKD
• Describe traditional therapies for CKD and their effect on kidney outcomes
• Memorize kidney outcomes of SGLT2i trials
• Explain how SGLT2i may result in beneficial effects
• Describe new developments in the nephrology field
• Recall the design of new kidney outcomes trials

Expert faculty

• Mark Cooper, MD - Inaugural Head of the Department of Diabetes, Central Clinical School, Monash University, Melbourne, Australia.

• Maria Rosa Costanzo, MD is a cardiologist and medical director for heart failure research at the Advocate Heart Institute in Naperville, IL, USA.

• Prof. Christoph Wanner, MD, Division of Nephrology and Hypertension at the University Hospital of Würzburg, Germany.

Target audience

This educational activity is designed for cardiologists in secondary care and other healthcare professionals with an interest in treating CKD patients.

CME accreditation

This online course is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit.

Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.